Clinical factors affecting progression-free survival with crizotinib in ALK-positive non-small cell lung cancer

BACKGROUND/AIMS: Although crizotinib is standard chemotherapy for advanced anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC), clinical factors affecting progression-free survival (PFS) have not been reported. The purpose of this study was to identify clinical factors affec...

Descripción completa

Detalles Bibliográficos
Autores principales: Ock, Chan-Young, Yoo, Shin-Hye, Keam, Bhumsuk, Kim, Miso, Kim, Tae Min, Jeon, Yoon Kyung, Kim, Dong-Wan, Chung, Doo Hyun, Heo, Dae Seog
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Association of Internal Medicine 2019
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6718771/
https://www.ncbi.nlm.nih.gov/pubmed/29950554
http://dx.doi.org/10.3904/kjim.2018.011

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6718771/
https://www.ncbi.nlm.nih.gov/pubmed/29950554
http://dx.doi.org/10.3904/kjim.2018.011

Ejemplares similares